Aegerion Pharmaceuticals Appoints Craig Fraser as Chief Operating Officer
Company Also Appoints Carolina Alarco to President, International and Johanna
Sealscott to Vice President, U.S. Sales
CAMBRIDGE, Mass., July 30, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc.(Nasdaq:AEGR), a biopharmaceutical company dedicated to the development
and commercialization of innovative therapies for patients with debilitating
rare diseases, today announced that Craig Fraser has been appointed as Chief
Operating Officer (COO).
Prior to his appointment as COO, Mr. Fraser served as President, U.S. and
International Commercial and Global Manufacturing and Supply Chain at
Aegerion, leading the launch of JUXTAPID® in the U.S. Prior to joining
Aegerion, Mr. Fraser held a number of commercial leadership positions at other
pharmaceutical companies, most recently as Vice President, Global Disease
Areas at Pfizer Inc. Prior to that, he was Vice President and Global Business
Manager at Wyeth, where he led the institutional business; and Vice President,
Commercial and Strategic Operations at Johnson & Johnson.
"Craig's leadership in the launch of JUXTAPID has demonstrated his ability to
build a global commercial organization, solve challenges and foster a
motivated and patient-focused culture," said Marc D. Beer, Chief Executive
Officer. "I have great confidence in Craig and believe that in his new role,
he will be instrumental in supporting Aegerion's continued growth through
Aegerion is also pleased to announce the appointment of Carolina Alarco to
President, International and Johanna Sealscott to Vice President, U.S. Sales.
Ms. Alarco previously held the position of Vice President & General Manager,
International, building Aegerion's international team and infrastructure in
markets outside the United States and European Union. Prior to Aegerion, Ms.
Alarco held various positions within Genzyme Corporation, most recently as
Vice-President of Commercial Operations for Latin America for the Renal &
Endocrinology Business Units.
Ms. Sealscott joined Aegerion in 2013 as a Regional Sales Director for
JUXTAPID. Prior to joining Aegerion, Ms. Sealscott was Senior Sales Director
for Optimer Pharmaceuticals, and before that, she was Clinical Sales Director
for Intuitive Surgical. Prior to Intuitive, Ms. Sealscott held various sales
leadership roles within The Medicines Company.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative therapies for patients with
debilitating rare diseases. For more information about the company, please
CONTACT: Aegerion Pharmaceuticals, Inc.
Amanda Murphy, Manager, Investor & Public Relations
Aegerion Pharmaceuticals, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.